LAVA Therapeutics (NASDAQ:LVTX) Issues Quarterly Earnings Results, Beats Expectations By $0.05 EPS

LAVA Therapeutics (NASDAQ:LVTX) issued its quarterly earnings data on Tuesday. The company reported ($0.31) EPS for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.05, Yahoo Finance reports. LAVA Therapeutics had a negative net margin of 228.02% and a negative return on equity of 51.90%.

LAVA Therapeutics Stock Up 3.9 %

NASDAQ:LVTX traded up $0.07 during mid-day trading on Thursday, reaching $1.87. The stock had a trading volume of 36,110 shares, compared to its average volume of 751,312. The stock’s 50 day simple moving average is $1.93 and its two-hundred day simple moving average is $2.41. LAVA Therapeutics has a 1-year low of $1.13 and a 1-year high of $6.47. The company has a market capitalization of $47.40 million, a price-to-earnings ratio of -1.67 and a beta of 0.54. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.42 and a quick ratio of 7.42.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. HC Wainwright restated a “buy” rating and set a $6.00 price objective on shares of LAVA Therapeutics in a research note on Friday, June 28th. JMP Securities reissued a “market outperform” rating and set a $6.00 price target on shares of LAVA Therapeutics in a research report on Wednesday.

LAVA Therapeutics Company Profile

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.